Headlines about Allscripts Healthcare Solutions (NASDAQ:MDRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Allscripts Healthcare Solutions earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave media coverage about the software maker an impact score of 45.09864260079 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Allscripts Healthcare Solutions (NASDAQ MDRX) traded down $0.02 during trading on Friday, hitting $14.55. 1,603,250 shares of the stock were exchanged, compared to its average volume of 2,356,031. The company has a current ratio of 0.98, a quick ratio of 0.98 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $2,630.00, a price-to-earnings ratio of -12.54, a P/E/G ratio of 2.60 and a beta of 1.34. Allscripts Healthcare Solutions has a one year low of $10.19 and a one year high of $15.20.
A number of research firms recently commented on MDRX. Royal Bank of Canada began coverage on Allscripts Healthcare Solutions in a research note on Tuesday, September 19th. They issued an “outperform” rating and a $17.00 target price on the stock. Robert W. Baird reissued a “buy” rating and issued a $16.00 target price on shares of Allscripts Healthcare Solutions in a research note on Tuesday, October 17th. KeyCorp reissued a “hold” rating on shares of Allscripts Healthcare Solutions in a research note on Friday, October 27th. Cowen raised Allscripts Healthcare Solutions from a “market perform” rating to an “outperform” rating and increased their target price for the company from $13.00 to $16.00 in a research note on Monday, September 11th. Finally, Dougherty & Co reissued a “buy” rating and issued a $16.00 target price (up previously from $15.00) on shares of Allscripts Healthcare Solutions in a research note on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $15.06.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Allscripts Healthcare Solutions (MDRX) Stock Price” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/12/29/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-allscripts-healthcare-solutions-mdrx-stock-price.html.
Allscripts Healthcare Solutions Company Profile
Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.
Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.